Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00915473 · ClinicalTrials.gov registry record · Phase 4

Greater Occipital Nerve Block for Migraine Prophylaxis

A Phase 4 study of Migraine Headache, sponsored by Mayo Clinic.

Completed
Registry status
Phase 4
Development phase
70
Enrollment target
1
Study location

NCT00915473 is a Phase 4 study of Migraine Headache that has completed, run by Mayo Clinic. The registered enrollment target is 70 participants, below the 148-participant average among 6 other Migraine Headache trials with a reported enrollment target (53% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00915473, a Phase 4 study of Migraine Headache, has completed, sponsored by Mayo Clinic.

COMPLETED
Registry status
Phase 4
Development phase
70 participants
Enrollment target
1
Study location

Study Summary

Migraine is a common neurological condition that can be disabling, particularly if chronic. Greater occipital nerve (GON) block has been utilized for decades for the treatment of migraine in the absence of a single randomized, placebo-controlled trial documenting its effectiveness. Hypothesis: Greater occipital nerve block reduces the frequency of days with moderate or severe headache in patients with episodic or chronic migraine.

Conditions Studied

Interventions

  • DRUG methylprednisolone
  • DRUG normal saline
  • DRUG lidocaine
  • DRUG bupivicaine

Study Locations (1)

Arizona

  • Mayo Clinic - Phoenix

Trial Details

FieldValue
Enrollment Target 70 participants
Start Date 2009-06
Est. Completion 2013-01
Phase Phase 4

Sponsor

Mayo Clinic

2,844 total trials

What the Registry Record Tells You About NCT00915473

The ClinicalTrials.gov registry entry for NCT00915473 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 70 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 148-participant average among 6 other Migraine Headache trials with a reported enrollment target (53% lower). The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Migraine Headache appearing as the primary indexed condition, and to 4 interventions - of which methylprednisolone is the first listed.

NCT00915473 reports 1 study location spanning 1 distinct geographic area - top geographies include Arizona.

Frequently Asked Questions

What is clinical trial NCT00915473 about?

NCT00915473 is a clinical study titled "Greater Occipital Nerve Block for Migraine Prophylaxis". Migraine is a common neurological condition that can be disabling, particularly if chronic. Greater occipital nerve (GON) block has been utilized for decades for the treatment of migraine in the absence of a single randomized, placebo-controlled trial documenting its effectiveness. Hypothesis: Grea...

What is the current status of trial NCT00915473?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 70 participants. The study started on 2009-06. Estimated completion is 2013-01.

What conditions does trial NCT00915473 study?

This clinical trial studies the following conditions: Migraine Headache.

What interventions are being tested in trial NCT00915473?

The interventions under investigation include: methylprednisolone (DRUG), normal saline (DRUG), lidocaine (DRUG), bupivicaine (DRUG).

Who is sponsoring clinical trial NCT00915473?

This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00915473 being conducted?

This trial has 1 study location across Arizona. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Migraine Headache

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.